This trial is evaluating whether ARN-509 (Phase 2) will improve 1 primary outcome and 4 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Week 12.
This trial requires 127 total participants across 4 different treatment groups
This trial involves 4 different treatments. ARN-509 (Phase 2) is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Although the number of cases of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) reported to the National Cancer Institute was relatively stable over this period, there was a marked increase in recorded incidence of metastases between 1987 and 1992; this suggests the need for further studies to refine the risk assessment for localized prostate cancer. Also, in the general population the detection rate of prostate cancer has increased over this period.
Treatment of prostate cancer is complex and tailored to the individual patient at a time when the prognostic factors have been considered for an individual patient. One of the most commonly used treatments for prostate cancer is radiotherapy and the use of androgen deprivation therapy is another popular treatment for prostate cancer as well as the use of other androgen antagonists such as orteronel and bicalutamide.
A causal connection to lifestyle factors, such as smoking, is strongly supported. The current recommendations by the USPSTF and the American Academy of Family Physicians are reasonable in regards to minimizing smoking and limiting alcohol. Dietary habits such as a healthy diet and exercise are also shown to be key factors in prostate cancer prevention. However, other lifestyle factors, such as caffeine and obesity, may not play a role; they should therefore be questioned while taking into account the possible deleterious effects.
Prostate cancer occurs when cells in the prostate grow uncontrollably and then form a mass. Once a prostate tumor emerges in one of the prostate glands it can quickly spread to nearby tissue. Prostate cancer often presents with urinary symptoms and frequent urination, painful urination or painful ejaculation and it is more likely to be high grade. The most common form is known as prostatitis or inflammation. Prostatic cancer can be detected using a digital rectal exam, computer-enhanced or transrectal ultrasound, a CT scan of the pelvis or MRI of the whole body. If a mass can be detected through a rectal exam prostatic cancer occurs in less than 2% of cases.
There are many signs of prostate cancer that include increased frequency and duration of urination, pain on urination and urgency. Abnormalities in volume and consistency of bladder and prostatic fluid, however, are not signs of prostate cancer.
In this article the question is answered, 'can prostate cancer be cured?' There is no such thing; treatment and diagnosis and management cannot cure a disease by itself. Effective treatment of concurrent diseases, as well as adherence to rigorous treatment protocols of prostate cancer is essential in reducing mortality, disease recurrence, prostate cancer-related morbidity, and disease-free survival from prostate cancer.
Arn-509 is an orally bioavailable, safe, and tolerable investigational drug candidate that is being used in the treatment of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). Unlike many other investigational antiandrogens and antiestrogens, arn-509 reversibly and selectively induces profound aromatase inhibition in prostate cancer cells, as well as in several human prostate tumor xenografts, without concomitant estrogenic or antiestrogenic effects.
There is a clear increase in the average age patients are diagnosed with prostate cancer in the United States. This rise is expected as younger men are more likely to be screened, and as treatment is becoming more available. However, the average age at initial diagnosis of prostate cancer remains unchanged at 72 years. The shift to earlier detection is in part driven by increased use of the PSA test and subsequent PSA trend screening. In the foreseeable future, the average age of prostate cancer diagnosis will likely increase due to the increase in use of screening and diagnostic testing for prostate cancer.
The number of discoveries in [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) research has dramatically increased. A major focus in prostate research should continue to be directed toward the development of drugs that can be used in conjunction with existing standard treatments to improve outcome. In particular, combination therapy may be superior to the standard method of treating patients with high-risk disease.
ARN-509 treatment demonstrates an increase in prostate-specific antigen levels in patients with previously untreated prostate cancer with an indication of biochemical response. In addition to the clinical benefit of a reduction in progression, the benefit/risk ratio showed the ability to reduce castration resistance. This data suggests a possible applicability for this drug in the management of androgen-dependent prostate cancer.
There has been little information published from genome-wide association studies to support the existence of genetic susceptibility factors or modifier gene effects for familial prostate cancer. We have evaluated the family history of prostate cancer in a large, population-based sample in Canada.
Results of phase II trials indicate that arn-509 is well tolerated in this patient population and has activity of a novel type. Further development is planned for the therapeutic use of this agent.